ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Clinical trials for ERYTHROPOIETIC PROTOPORPHYRIA (EPP) explained in plain language.
Never miss a new study
Get alerted when new ERYTHROPOIETIC PROTOPORPHYRIA (EPP) trials appear
Sign up with your email to follow new studies for ERYTHROPOIETIC PROTOPORPHYRIA (EPP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug could let Sun-Sensitive patients enjoy the outdoors Pain-Free
Disease control OngoingThis study tests whether the drug bitopertin can help people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP) spend more time in sunlight without pain. About 183 participants aged 12 and older will receive either bitopertin or a placebo for 6 months. Rese…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New pill could let sun-sensitive patients enjoy daylight longer without burning pain.
Symptom relief OngoingThis study tests an experimental drug called MT-7117 in 165 adults and teens (ages 12-75) with erythropoietic protoporphyria or X-linked protoporphyria — rare conditions that cause severe pain, burning, or itching within minutes of sun exposure. Participants receive either the dr…
Matched conditions: ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated May 26, 2026 08:13 UTC